quote:
Op zondag 13 juni 2010 12:05 schreef gohan16 het volgende:Nee geen ervaring. zoek er maar eens op in pubmed. Wisselende geluiden als ik het even zo snel scna. Lange termijn effecten, dus de disease modifying effecten zijn niet bekend.
Ik had ook al even gepubmed. In een Cochrane review:
quote:
Main results
Twenty-two trials involving 979 patients were included. There were six trials of SLIT for house dust mite allergy, five for grass pollen, five for Parietaria, two for olive and one each for ragweed, cat, tree and Cupressus. Five studies enrolled exclusively children. Seventeen studies administered the allergen by sublingual drops subsequently swallowed, three by drops subsequently spat out and two by sublingual tablets. Eight studies involved treatment for less than six months, 10 studies for 6 to 12 months and four studies for greater than 12 months. All included studies were double-blind placebo-controlled trials of parallel group design. Concealment of treatment allocation was considered adequate in all studies and the use of identical placebo preparations was almost universal. There was significant heterogeneity, most likely due to widely differing scoring systems between studies, for most comparisons.
Overall there was a significant reduction in both symptoms (SMD -0.42, 95% confidence interval -0.69 to -0.15; p = 0.002) and medication requirements (SMD -0.43 [-0.63, -0.23]; p = 0.00003) following immunotherapy. Subgroup analyses failed to identify a disproportionate benefit of treatment according to the allergen administered. There was no significant reduction in symptoms and medication scores in those studies involving only children but total numbers of participants were too small to make this a reliable conclusion. Increasing duration of treatment does not clearly increase efficacy. The total dose of allergen administered may be important but insufficient data were available to analyse this factor.
Authors' conclusions
SLIT is a safe treatment which significantly reduces symptoms and medication requirements in allergic rhinitis. The size of this benefit compared to that of other available therapies, particularly injection immunotherapy, is not clear, having been assessed directly in very few studies. Further research is required concentrating on optimising allergen dosage and patient selection.
Wilson D, Torres-Lima M, Durham S. Sublingual immunotherapy for allergic rhinitis. Cochrane Database of Systematic Reviews 2003, Issue 2. Art. No.: CD002893. DOI: 10.1002/14651858.CD002893.
Maar goed, het is geen gevaarlijke therapie, dus ik wil dat risico denk ik wel nemen. Eens kijken of mijn huisarts er hetzelfde over denkt.
[ Bericht 2% gewijzigd door dotKoen op 13-06-2010 12:36:41 ]